Switching to biosimilars in the treatment of rheumatic diseases-Reference-Cited by-同舟云学术

Switching to biosimilars in the treatment of rheumatic diseases

Published:2018-07-03 Issue:7 Volume:14 Page:557-571
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Yoo Dae Hyun¹^ORCID,Choe Jung-Yoon²,Shim Seung Cheol³,Suh Chang-Hee⁴

Affiliation:

1. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

2. Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea

3. Division of Rheumatology, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea

4. Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea

Funder

not funded

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2018.1490178

Reference75 articles.

1. European Medicinal Agency: EMEA/CHMP/BMWP/42832/2005 Rev1. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Edited at 18 Dec 2014.

2. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database

3. Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study

5. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The landscape of biosimilars in Saudi Arabia: preparing for the next decade;Expert Opinion on Biological Therapy;2023-07-28

2. An Institutional Guide for Formulary Decisions of Biosimilars;Hospital Pharmacy;2022-11-29

3. A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006);Current Medical Research and Opinion;2022-04-17

4. Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis;Expert Opinion on Biological Therapy;2019-09-18

5. Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases;Expert Opinion on Biological Therapy;2019-05-06